CompletedPhase 2NCT01755507
Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis
Studying Primary sclerosing cholangitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dr. Falk Pharma GmbH
- Principal Investigator
- Michael Trauner, ProfMed. Uni Wien
- Intervention
- norUDCA(drug)
- Enrollment
- 159 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2012 – 2015
Study locations (3)
- Prof. M. Trauner, Vienna, Austria
- Prof. Michael Manns, Hanover, Germany
- Kirsten Boberg, Oslo, Norway
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01755507 on ClinicalTrials.govOther trials for Primary sclerosing cholangitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07229911A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)Takeda
- RECRUITINGPHASE2NCT06699121A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSCLISCure Biosciences
- RECRUITINGPHASE2NCT06905054Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver TransplantationMayo Clinic
- RECRUITINGNANCT06865924Colangioids to Define the Genetic Factors Involved in Atypical Primary Sclerosing CholangitisFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- RECRUITINGNCT06297993Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)PSC Partners Seeking a Cure
- RECRUITINGNANCT06351696The Effects of Bromelain Supplement in Patients With Ulcerative ColitisNational Nutrition and Food Technology Institute
- RECRUITINGPHASE2NCT06286709FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitisUniversity of Birmingham
- RECRUITINGEARLY PHASE1NCT06197308Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSCUniversity of Minnesota